Details
Stereochemistry | ACHIRAL |
Molecular Formula | C18H20N2O2S |
Molecular Weight | 328.429 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=CC(=N1)N(C)C(=S)OC2=CC=C3CCCCC3=C2
InChI
InChIKey=VPHPQNGOVQYUMG-UHFFFAOYSA-N
InChI=1S/C18H20N2O2S/c1-20(16-8-5-9-17(19-16)21-2)18(23)22-15-11-10-13-6-3-4-7-14(13)12-15/h5,8-12H,3-4,6-7H2,1-2H3
Molecular Formula | C18H20N2O2S |
Molecular Weight | 328.429 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/19194054Curator's Comment: description was created based on several sources, including
http://jocpr.com/vol5-iss11-2013/JCPR-2013-5-11-219-222.pdf
Sources: http://www.ncbi.nlm.nih.gov/pubmed/19194054
Curator's Comment: description was created based on several sources, including
http://jocpr.com/vol5-iss11-2013/JCPR-2013-5-11-219-222.pdf
Liranafate (6-methoxy-2-N-methyl-aminopyridine-thiocarboxylic acid-(5,6,7,8 tetrahydro)-β-Naphthyl ester), a new antifungal drug, is synthesis inhibitor of squalene epoxidase inhibitor and cytoderm inhibitor, which was manufactured by Tosoh Corporation and Zenyaku Kogyo Corporation. It firstly came to the market in August 2000 in Japan. By inhibiting the squalene epoxide reactions of fungal cells and detering the synthesis of ergosterol, which is a constituent of cell membrane. The antifungal activity of Liranafate is 8 times as high as that of Tolnaftate. Liranafate is especially effective against trichophyton rubrum.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Squalene epoxidase fungal |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Unknown Approved UseUnknown |
|||
Curative | Unknown Approved UseUnknown |
|||
Curative | Unknown Approved UseUnknown |
|||
Curative | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: http://pfxbzlx.gdvdc.com/EN/Y2008/V15/I01/12
2% cream applied once a day.
Route of Administration:
Topical
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/19001760
production of IL-8 was profoundly suppressed by the addition of liranaftate to the culture in a dose-dependent manner.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:08:43 GMT 2025
by
admin
on
Mon Mar 31 18:08:43 GMT 2025
|
Record UNII |
5253IGO5X3
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C514
Created by
admin on Mon Mar 31 18:08:43 GMT 2025 , Edited by admin on Mon Mar 31 18:08:43 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5253IGO5X3
Created by
admin on Mon Mar 31 18:08:43 GMT 2025 , Edited by admin on Mon Mar 31 18:08:43 GMT 2025
|
PRIMARY | |||
|
C66019
Created by
admin on Mon Mar 31 18:08:43 GMT 2025 , Edited by admin on Mon Mar 31 18:08:43 GMT 2025
|
PRIMARY | |||
|
6744
Created by
admin on Mon Mar 31 18:08:43 GMT 2025 , Edited by admin on Mon Mar 31 18:08:43 GMT 2025
|
PRIMARY | |||
|
DTXSID6046470
Created by
admin on Mon Mar 31 18:08:43 GMT 2025 , Edited by admin on Mon Mar 31 18:08:43 GMT 2025
|
PRIMARY | |||
|
100000082522
Created by
admin on Mon Mar 31 18:08:43 GMT 2025 , Edited by admin on Mon Mar 31 18:08:43 GMT 2025
|
PRIMARY | |||
|
1586
Created by
admin on Mon Mar 31 18:08:43 GMT 2025 , Edited by admin on Mon Mar 31 18:08:43 GMT 2025
|
PRIMARY | |||
|
3936
Created by
admin on Mon Mar 31 18:08:43 GMT 2025 , Edited by admin on Mon Mar 31 18:08:43 GMT 2025
|
PRIMARY | |||
|
Liranaftate
Created by
admin on Mon Mar 31 18:08:43 GMT 2025 , Edited by admin on Mon Mar 31 18:08:43 GMT 2025
|
PRIMARY | |||
|
C470235
Created by
admin on Mon Mar 31 18:08:43 GMT 2025 , Edited by admin on Mon Mar 31 18:08:43 GMT 2025
|
PRIMARY | |||
|
CHEMBL1591365
Created by
admin on Mon Mar 31 18:08:43 GMT 2025 , Edited by admin on Mon Mar 31 18:08:43 GMT 2025
|
PRIMARY | |||
|
m6840
Created by
admin on Mon Mar 31 18:08:43 GMT 2025 , Edited by admin on Mon Mar 31 18:08:43 GMT 2025
|
PRIMARY | Merck Index | ||
|
SUB08528MIG
Created by
admin on Mon Mar 31 18:08:43 GMT 2025 , Edited by admin on Mon Mar 31 18:08:43 GMT 2025
|
PRIMARY | |||
|
88678-31-3
Created by
admin on Mon Mar 31 18:08:43 GMT 2025 , Edited by admin on Mon Mar 31 18:08:43 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |